Taigen Biopharmaceuticals Holdings Ltd

4157 · TWO · Healthcare / Biotechnology

8.78TWD+0.56 (+6.81%)

Price History

Full chart

Market Stats

Previous Close8.22

Open8.25

Day Range8.25 – 8.78

52-Week Range7.73 – 16.40

Volume1.57M

Market Cap6.16B

P/E (TTM)41.19

Forward P/E0.00

EPS0.21

Dividend Yield0.00%

Beta0.22

50-Day Avg8.77

200-Day Avg10.40

About

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMs. Li-Wen Chang
Employees0
HeadquartersNo. 138, Xinming Road, Taipei, Taiwan, 11470, Taiwan
Websitehttps://www.taigenbiotech.com.tw

Leadership

Ms. Li-Wen ChangPresident & VP of Clinical Development Division
Mr. Mark KaoHead of the Accounting Department
Dr. Ming-Chu Hsu Ph.D.Founder
Dr. Peter W. Tsao M.B.A., Ph.D.Vice President Corporate Development

Financials

Income Statement

Currency: TWD	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	14.91M	225.73M	40.44M	69.88M	104.60M	78.00M	146.02M	553.21M	29.62M	20.31M	23.42M	1.29B	36.23M	123.13M	150.65M	259.47M
Growth (%)	-	+1414.37%	-82.08%	+72.79%	+49.69%	-25.42%	+87.20%	+278.86%	-94.65%	-31.41%	+15.30%	+5426.95%	-97.20%	+239.87%	+22.35%	+72.24%
Cost of Revenue	11.54M	28.97M	12.15M	15.27M	17.56M	19.87M	15.39M	6.25M	3.56M	7.60M	4.04M	12.72M	3.74M	39.05M	16.13M	18.17M
Gross Profit	3.36M	196.76M	28.29M	54.61M	87.03M	58.14M	130.63M	546.96M	26.05M	12.71M	19.39M	1.28B	32.49M	84.08M	134.52M	241.30M
Gross Margin	22.56%	87.16%	69.96%	78.15%	83.21%	74.53%	89.46%	98.87%	87.97%	62.57%	82.77%	99.02%	89.69%	68.28%	89.29%	93.00%
Operating Expense	454.45M	412.65M	524.54M	551.19M	495.63M	489.35M	368.34M	286.53M	284.45M	299.75M	423.17M	405.56M	249.64M	258.78M	256.62M	171.91M
Operating Income	-451.08M	-215.90M	-496.24M	-496.58M	-408.59M	-431.21M	-237.71M	260.43M	-258.40M	-287.04M	-403.78M	876.24M	-217.15M	-174.70M	-122.10M	69.39M
Operating Margin	-3026.19%	-95.64%	-1227.11%	-710.67%	-390.63%	-552.80%	-162.79%	47.08%	-872.43%	-1412.99%	-1723.95%	67.69%	-599.37%	-141.88%	-81.05%	26.74%
EBITDA	1.41B	-548.69M	-484.34M	-487.07M	-400.01M	-418.99M	-227.80M	270.61M	-248.24M	-252.72M	-372.35M	905.10M	-188.60M	-147.09M	-6.63M	76.58M
EBITDA Margin	9483.41%	-243.07%	-1197.67%	-697.06%	-382.43%	-537.14%	-156.00%	48.92%	-838.14%	-1244.05%	-1589.76%	69.92%	-520.58%	-119.46%	-4.40%	29.51%
Net Income	-2.29B	42.84M	-468.40M	-432.19M	-403.72M	-412.99M	-250.03M	746.38M	-343.21M	-295.69M	-404.82M	775.62M	-237.16M	136.73M	-38.58M	45.18M
Net Income Margin	-15333.54%	18.98%	-1158.25%	-618.52%	-385.97%	-529.45%	-171.23%	134.92%	-1158.79%	-1455.57%	-1728.37%	59.92%	-654.61%	111.04%	-25.61%	17.41%
R&D	381.65M	323.98M	415.05M	440.37M	386.10M	401.44M	263.90M	190.68M	197.55M	223.56M	249.44M	283.28M	237.52M	187.48M	166.07M	96.88M
R&D as % of Total Revenue	2560.36%	143.53%	1026.32%	630.23%	369.12%	514.64%	180.73%	34.47%	666.99%	1100.51%	1064.98%	21.88%	655.60%	152.26%	110.23%	37.34%
Interest Expense	0	0	0	0	0	0	0	0	0	1.03M	601.00K	244.00K	854.00K	1.14M	1.42M	1.67M
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.07%	2.57%	0.02%	2.36%	0.92%	0.95%	0.64%

Balance Sheet

Currency: TWD	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.11B	610.52M	733.95M	486.49M	1.10B	625.46M	823.45M	1.52B	1.19B	946.11M	556.45M	1.39B	1.05B	1.23B	1.17B	1.17B
Total Liabilities	5.40B	97.31M	361.15M	332.71M	246.05M	183.86M	147.82M	97.71M	94.36M	130.92M	114.26M	139.11M	76.98M	110.94M	91.96M	92.38M
Total Equity	-4.29B	513.21M	372.80M	153.77M	852.14M	441.60M	675.62M	1.42B	1.09B	815.18M	442.18M	1.25B	970.03M	1.12B	1.08B	1.07B
Cash	867.03M	492.72M	634.56M	310.75M	99.59M	110.41M	158.43M	183.31M	148.10M	136.26M	60.85M	364.93M	243.11M	374.65M	74.14M	145.09M
Total Debt	-	-	-	-	-	-	-	-	-	66.19M	17.12M	53.46M	38.47M	74.69M	-	-
Net Debt	-867.03M	-492.72M	-634.56M	-310.75M	-99.59M	-110.41M	-158.43M	-183.31M	-148.10M	-70.06M	-43.73M	-311.47M	-204.64M	-299.97M	-	-

Cash Flow

Currency: TWD	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-196.43M	-379.23M	-141.36M	-458.46M	-540.03M	-592.56M	-152.83M	-266.93M	-254.93M	-342.52M	-242.10M	629.07M	-21.27M	20.74M	-173.09M	20.93M
Investing Cash Flow	17.71M	-	-	-	-	602.70M	-277.34M	291.45M	220.03M	322.20M	216.10M	-306.07M	-84.95M	-	-	-
Financing Cash Flow	235.32M	11.47M	301.03M	200.39M	1.10B	74.00K	480.20M	9.13M	9.13M	9.13M	-49.65M	-18.85M	-15.84M	-19.99M	-	-
Capital Expenditure	11.78M	10.23M	8.42M	10.87M	11.30M	15.33M	10.67M	18.08M	22.97M	5.06M	8.41M	11.83M	7.46M	7.39M	2.70M	4.50M
Free Cash Flow	-208.21M	-389.46M	-149.78M	-469.33M	-551.34M	-607.89M	-163.50M	-285.01M	-277.89M	-347.58M	-250.51M	617.24M	-28.73M	13.35M	-175.78M	16.42M
FCF to OCF	106.00%	102.70%	105.96%	102.37%	102.09%	102.59%	106.98%	106.77%	109.01%	101.48%	103.47%	98.12%	135.09%	64.35%	101.56%	78.47%

Earnings

Report Date	Nov 13, 2013	May 14, 2014	Aug 11, 2014	Nov 25, 2014	May 14, 2015	Jun 30, 2015	Mar 24, 2016	Aug 13, 2020	Nov 5, 2020	Apr 28, 2021	Aug 31, 2021	Nov 3, 2021	Mar 15, 2022	Nov 2, 2022	Mar 9, 2023
EPS Estimate	-0.15	-0.09	-0.09	-0.15	-0.12	-0.09	-0.09	-0.11	-0.13	-0.08	0.27	0.24	-	-	-
EPS Actual	-0.22	-0.09	-0.19	-0.14	-0.07	-0.16	-0.17	-0.14	-0.14	-0.06	1.53	-0.19	-0.19	0.02	-0.16
Surprise	-46.67%	0.00%	-111.11%	6.67%	41.67%	-77.78%	-88.89%	-27.27%	-7.69%	25.00%	466.67%	-179.17%	-	-	-
Timing	After-hours	After-hours	After-hours	After-hours	After-hours	-	After-hours	Pre-market	Pre-market	After-hours	After-hours	Pre-market	After-hours	Pre-market	After-hours

Key Statistics & Ratios

Market Cap6.16B

Enterprise Value5.41B

Trailing P/E41.19

Forward P/E0.00

Price / Sales24.01

Price / Book6.18

EPS0.21

Book Value1.44

Revenue (TTM)256.46M

Gross Profit (TTM)240.28M

EBITDA85.39M

Profit Margin60.49%

Operating Margin-353.49%

Return on Equity15.55%

Return on Assets4.81%

Shares Outstanding711.83M

Shares Float436.76M

Beta0.22

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%